Login to Your Account


Novartis Passes on Idenix Lead HCV Antiviral Drug

By Catherine Hollingsworth


Monday, November 2, 2009
Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

NORTH AMERICA
Tel: +1-855-260-5607
Outside of the US
Tel. +44-203-684-1797
 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2017 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics